多巴胺受體D2
參考文獻

↑  .
↑  .
↑  .
1 2 3  GRCh38: Ensembl release 89: ENSG00000149295 - Ensembl, May 2017
1 2 3  GRCm38: Ensembl release 89: ENSMUSG00000032259 - Ensembl, May 2017
↑  . National Center for Biotechnology Information, U.S. National Library of Medicine.
↑  . National Center for Biotechnology Information, U.S. National Library of Medicine.
↑  Madras BK. . Journal of the History of the Neurosciences. 2013, 22 (1): 62–78. PMID 23323533. doi:10.1080/0964704X.2012.678199.
↑  Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E. . Nature. Nov 2000, 408 (6809): 199–203. PMID 11089973. doi:10.1038/35041572.
↑  Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A, Liu F, Mansuy IM, Roder JC. . Neuron. Sep 2009, 63 (5): 643–56. PMID 19755107. doi:10.1016/j.neuron.2009.08.014.
↑  Wiemerslage L, Schultz BJ, Ganguly A, Lee D. . Journal of Neurochemistry. Aug 2013, 126 (4): 529–40. PMID 23452092. doi:10.1111/jnc.12228.
↑  . （原始内容存档于2010-03-07）.
1 2 3  Beaulieu JM, Gainetdinov RR. . Pharmacological Reviews. Mar 2011, 63 (1): 182–217. PMID 21303898. doi:10.1124/pr.110.002642.
↑  UniProt 
P14416
↑  Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV. . Human Molecular Genetics. Feb 2003, 12 (3): 205–16. PMID 12554675. doi:10.1093/hmg/ddg055.
↑  Arinami T, Gao M, Hamaguchi H, Toru M. . Human Molecular Genetics. Apr 1997, 6 (4): 577–82. PMID 9097961. doi:10.1093/hmg/6.4.577.
↑  Glatt SJ, Faraone SV, Tsuang MT. . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. Jul 2004, 128B (1): 21–3. PMID 15211624. doi:10.1002/ajmg.b.30007.
↑  Lucht M, Rosskopf D. . Science. Jul 2008, 321 (5886): 200; author reply 200. PMID 18621654. doi:10.1126/science.1155372.
↑  Wang J, Liu ZL, Chen B. . Neurology. Jun 2001, 56 (12): 1757–9. PMID 11425949. doi:10.1212/WNL.56.12.1757.
↑  Wang J, Zhao C, Chen B, Liu ZL. . Neuroscience Letters. Jan 2004, 355 (3): 193–6. PMID 14732464. doi:10.1016/j.neulet.2003.11.006.
↑  . RxList.com. 2010-01-21  [2010-01-21]. （原始内容存档于2010-01-18）.
↑  Holmes IP, Blunt RJ, Lorthioir OE, Blowers SM, Gribble A, Payne AH, Stansfield IG, Wood M, Woollard PM, Reavill C, Howes CM, Micheli F, Di Fabio R, Donati D, Terreni S, Hamprecht D, Arista L, Worby A, Watson SP. . Bioorganic & Medicinal Chemistry Letters. Mar 2010, 20 (6): 2013–6. PMID 20153647. doi:10.1016/j.bmcl.2010.01.090.
↑  Giacomelli S, Palmery M, Romanelli L, Cheng CY, Silvestrini B. . Life Sciences. 1998, 63 (3): 215–22. PMID 9698051. doi:10.1016/S0024-3205(98)00262-8.
↑  Wang GJ, Volkow ND, Thanos PK, Fowler JS. . Journal of Addictive Diseases. 2004, 23 (3): 39–53. PMID 15256343. doi:10.1300/J069v23n03_04.
↑  Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR. . Pharmacology. 2013, 92 (1–2): 84–9. PMID 23942137. doi:10.1159/000351971.
↑  Agnati LF, Ferré S, Genedani S, Leo G, Guidolin D, Filaferro M, Carriba P, Casadó V, Lluis C, Franco R, Woods AS, Fuxe K. . Journal of Proteome Research. Nov 2006, 5 (11): 3077–83. PMID 17081059. doi:10.1021/pr0601382.
↑  Beyaert MG, Daya RP, Dyck BA, Johnson RL, Mishra RK. . European Neuropsychopharmacology. Mar 2013, 23 (3): 253–62. PMID 22658400. doi:10.1016/j.euroneuro.2012.04.010.
↑  Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, López L, Scammells PJ, Capuano B, Sexton PM, Javitch JA, Christopoulos A. . Nature Chemical Biology. Sep 2014, 10 (9): 745–52. PMID 25108820. doi:10.1038/nchembio.1593.
↑  Maggio R, Scarselli M, Capannolo M, Millan MJ. . European Neuropsychopharmacology. Sep 2015, 25 (9): 1470–9. PMID 25453482. doi:10.1016/j.euroneuro.2014.09.016.
↑  Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R. . Molecular Pharmacology. Nov 2010, 78 (5): 925–34. PMC 2981362 . PMID 20702763. doi:10.1124/mol.110.065755.
↑  Möller D, Kling RC, Skultety M, Leuner K, Hübner H, Gmeiner P. . Journal of Medicinal Chemistry. Jun 2014, 57 (11): 4861–75. PMID 24831693. doi:10.1021/jm5004039.
↑  Binda AV, Kabbani N, Lin R, Levenson R. . Molecular Pharmacology. Sep 2002, 62 (3): 507–13. PMID 12181426. doi:10.1124/mol.62.3.507.
↑  Smith FD, Oxford GS, Milgram SL. . The Journal of Biological Chemistry. Jul 1999, 274 (28): 19894–900. PMID 10391935. doi:10.1074/jbc.274.28.19894.
↑  Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R. . The Journal of Neuroscience. Oct 2002, 22 (19): 8476–86. PMID 12351722.
↑  Beaulieu JM, Espinoza S, Gainetdinov RR. . British Journal of Pharmacology. Jan 2015, 172 (1): 1–23. PMC 4280963 . PMID 25671228. doi:10.1111/bph.12906.
↑  Grandy DK, Miller GM, Li JX. . Drug Alcohol Depend. February 2016, 159: 9–16. PMID 26644139. doi:10.1016/j.drugalcdep.2015.11.014. This original observation of TAAR1 and DA D2R interaction has subsequently been confirmed and expanded upon with observations that both receptors can heterodimerize with each other under certain conditions ... Additional DA D2R/TAAR1 interactions with functional consequences are revealed by the results of experiments demonstrating that in addition to the cAMP/PKA pathway (Panas et al., 2012) stimulation of TAAR1-mediated signaling is linked to activation of the Ca++/PKC/NFAT pathway (Panas et al.,2012) and the DA D2R-coupled, G protein-independent AKT/GSK3 signaling pathway (Espinoza et al., 2015; Harmeier et al., 2015), such that concurrent TAAR1 and DA DR2R activation could result in diminished signaling in one pathway (e.g. cAMP/PKA) but retention of signaling through another (e.g., Ca++/PKC/NFA)
↑  Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, Dernick G, Wettstein JG, Iglesias A, Rolink A, Bettler B, Hoener MC. . Eur Neuropsychopharmacol. 2015, 25 (11): 2049–61. PMID 26372541. doi:10.1016/j.euroneuro.2015.08.011. Interaction of TAAR1 with D2R altered the subcellular localization of TAAR1 and increased D2R agonist binding affinity.
↑  Maggio R, Millan MJ. . Current Opinion in Pharmacology. Feb 2010, 10 (1): 100–7. PMID 19896900. doi:10.1016/j.coph.2009.10.001.
↑  Hasbi A, O'Dowd BF, George SR. . Current Opinion in Pharmacology. Feb 2010, 10 (1): 93–9. PMC 2818238 . PMID 19897420. doi:10.1016/j.coph.2009.09.011.
↑  Albizu L, Holloway T, González-Maeso J, Sealfon SC. . Neuropharmacology. Sep 2011, 61 (4): 770–7. PMC 3556730 . PMID 21645528. doi:10.1016/j.neuropharm.2011.05.023.